57th European Renal Association & European Dialysis and Transplant Association Congress (ERA-EDTA 2020)

Milan 06 June 2020 - 09 June 2020

Avacopan trumps steroids for ANCA-associated vasculitis

25 Sep 2020 by

Avacopan, the oral inhibitor of complement activation, yields significant sustained remission compared with standard treatment with steroids in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), the ADVOCATE study shows.

Avacopan trumps steroids for ANCA-associated vasculitis

25 Sep 2020

High-dose IV iron cuts risk of classic MI in CKD

01 Jul 2020 by

Proactive treatment with high-dose intravenous (IV) iron reduces the risk for type 1 or classic myocardial infarction (MI), but not type 2 MI, in patients with chronic kidney disease (CKD) on dialysis, according to a prespecified secondary analysis of the PIVOTAL study.

High-dose IV iron cuts risk of classic MI in CKD

01 Jul 2020

HK in CKD: Do diet, HD frequency matter?

28 Jun 2020 by

Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.

HK in CKD: Do diet, HD frequency matter?

28 Jun 2020

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

28 Jun 2020 by

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.

No increased ophthalmic risk with roxadustat treatment in DD CKD-related anaemia

28 Jun 2020

Roxadustat a new option for CKD-related anaemia

27 Jun 2020 by

Roxadustat may be a suitable treatment for anaemia in patients with non-dialysis dependent (NDD) chronic kidney disease (CKD), the phase III Dolomites* study showed.

Roxadustat a new option for CKD-related anaemia

27 Jun 2020

SNF472 slows CAC progression in haemodialysis patients

20 Jun 2020 by

SNF472 treatment resulted in a significantly slower progression of coronary artery calcium (CAC) in patients with end-stage renal disease (ESRD) receiving haemodialysis, according to a prespecified subgroup analysis of the CaLIPSO* study presented at ERA-EDTA 2020.

SNF472 slows CAC progression in haemodialysis patients

20 Jun 2020

AURORA shines light on novel drug for lupus nephritis

18 Jun 2020 by

The novel calcineurin inhibitor (CNI) voclosporin showed superiority over placebo on a background of standard-of-care (SOC) in patients with active lupus nephritis (LN), the AURORA* trial has shown.

AURORA shines light on novel drug for lupus nephritis

18 Jun 2020

eGFR dip does not influence outcomes in T2D patients on empagliflozin

17 Jun 2020 by

An eGFR* decline of >10 percent did not appear to influence kidney outcomes in individuals receiving empagliflozin for type 2 diabetes, according to data presented at ERA-EDTA 2020.

eGFR dip does not influence outcomes in T2D patients on empagliflozin

17 Jun 2020

Haemodialysis tied to higher paediatric MAP-SDS than hemodiafiltration

17 Jun 2020 by

Children undergoing haemodialysis (HD) may experience a higher mean arterial pressure standard deviation score (MAP-SDS) over time compared with those undergoing hemodiafiltration (HDF), according to a study presented at ERA-EDTA 2020.

Haemodialysis tied to higher paediatric MAP-SDS than hemodiafiltration

17 Jun 2020

Belimumab improves renal response in lupus nephritis

16 Jun 2020 by

Adding belimumab to standard maintenance therapy significantly improves renal response in patients with active lupus nephritis compared with standard therapy alone, according to the BLISS-LN study presented at the ERA-EDTA 2020 Meeting.

Belimumab improves renal response in lupus nephritis

16 Jun 2020